Understand the source comparison
Peptides for Panic Disorder Protocol Evidence Guide: Comparison
Cerebrolysin BDNF upregulation, synaptic plasticity enhancement Accelerates fear extinction 40–60% in conditioned fear models (rodent) Open-label trials in PTSD show 34% symptom reduction; no panic-specific trials Addresses neuroplasticity deficits that preven
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- BDNF upregulation, synaptic plasticity enhancement
- Accelerates fear extinction 40–60% in conditioned fear models (rodent)
- Open-label trials in PTSD show 34% symptom reduction; no panic-specific trials
- Addresses neuroplasticity deficits that prevent fear extinction; most direct mechanism for panic pathophysiology
- Strongest preclinical rationale but lacks panic-specific clinical data. Research use only
- Dihexa
- HGF receptor activation, synaptogenesis
- Increases hippocampal dendritic spine density 250% in aged rats
- Phase I cognitive trials in healthy adults; no anxiety disorder trials
- May reverse hippocampal atrophy seen in chronic panic disorder; cognitive restoration potential
- Promising for structural brain changes but mechanism too slow for acute panic relief
- Thymalin
- HPA axis normalization, cortisol regulation
- Reduces basal cortisol 28% in chronic stress models (rodent)
- Case series in occupational stress (cosmonauts); no psychiatric trials
- Targets HPA axis hyperreactivity directly; addresses cortisol dysregulation in panic
- Mechanistically sound but weakest clinical evidence base. Early-stage research only
- P21
- CREB enhancement, long-term potentiation facilitation
- Reduces freezing behavior 58% during fear extinction (rodent)
- No human trials in any indication
- Facilitates extinction learning. The exact deficit in panic disorder maintenance
- Mechanistically elegant but zero human safety/efficacy data. Pure preclinical stage